HCC1569(人乳腺癌細(xì)胞)
CBP60372
                       
                         詢  價(jià)
                        
                        
                索取STR
                        
                    產(chǎn)品描述
                    產(chǎn)品數(shù)據(jù)庫
                    
                | I. General information | |
| Synonyms: | HCC1569 | 
| Background: | The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation. This cell line was initiated on 3/8/95 and took 19 months to establish.  | 
		
| Species: | Homo sapiens, human | 
| Tissue: | mammary gland; breast | 
| Disease: | TNM stage IV, grade 3, primary metaplastic carcinoma | 
| Gender: | female, 70 years, Black | 
| Morphology: | epithelial | 
| Growth Mode: | mixed adherent-suspension | 
| Culture Medium: | 
				 RPMI-1640+20%FBS HCC1569完全培養(yǎng)基,# CBP60372M  | 
		
| Cryopreservation medium: | 90%FBS+10%DMSO | 
| Receptor Expression: | estrogen receptor, negative progesterone receptor, negative  | 
		
| Oncogene: | her2/neu +, p53 - | 
| Genes Expressed: | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 | 
| Cellular Products: | Epithelial glycoprotein 2 [EGP2]; cytokeratin 19 | 
| Comments: | The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis. The cells are poorly differentiated. The cells are positive for expression of Her2-neu and negative for expression of p53. HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay. For more information, please contact us (4008-750-250).  |